Premium
Clinical melperone treatment blocks D 2 ‐dopamine receptors in the human brain as determined by PET
Author(s) -
Wiesel F.A.,
Farde L.,
Halidin C.
Publication year - 1989
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1989.tb06433.x
Subject(s) - raclopride , dopamine , human brain , receptor , dopamine receptor , positron emission tomography , pharmacology , medicine , chemistry , endocrinology , nuclear medicine , neuroscience , psychology
Positron emission tomography and 11‐C‐labelled raclopride was used to determine central D 2 ‐dopamine receptor occupancy in three melperone treated patients. Treatment with melperone in daily doses of 250 and 300 mg for 3 to 6 weeks, resulted in a receptor occupancy above 70%. Thus, clinical doses of melperone as we previously demonstrated for several classical neuroleptics cause a substantial D 2 ‐dopamine receptor blockade in the human brain in vivo .